Stock listing

LSE:GENF Genflow Biosciences PLC Share Price

Home listing (LSE) of Genflow Biosciences PLC

Follow Genflow Biosciences PLC into a list and get an email when it puts out news.

Share price · LSE:GENF

1.55p GBX (pence) -0.05 (-3.1%)

Close on Nov 20, 2026

Past year -16.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
1.50p – 1.65p GBX (pence)Nov 20, 2026
Volume
1.06M sharesNov 20, 2026
Market cap
£9.22M GBPAt the close on Nov 20, 2026 · price × 594.5M shares outstanding
52-week range
1.21p – 3.12p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
£42,314 GBPMedian day 925,096 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Genflow Biosciences PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:GENF · Home1.55p GBX (pence)-0.05 (-3.1%)1,059,0861.60p1.65p1.50p1.60pClose on Nov 20, 2026
OTC:GENFF$0.028 USD-0.002 (-6.7%)200$0.028$0.028$0.028$0.030Close on Nov 20, 2026
Frankfurt:WQ5€0.018 EUR-0.001 (-5.4%)—€0.015€0.019€0.015€0.019Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:GENF · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
1.55p-0.05-3.1%1.60p1.65p1.50p1,059,086
1.60p-0.025-1.5%1.607p1.636p1.55p634,608
1.625p-0.025-1.5%1.617p1.65p1.615p275,127
1.65p0.000.0%1.65p1.69p1.65p65,607
1.65p0.000.0%1.659p1.70p1.60p62,797
1.65p0.000.0%1.605p1.735p1.60p471,154
1.65p+0.025+1.5%1.65p1.68p1.605p432,505
1.625p-0.11-6.3%1.65p1.65p1.60p730,762
1.735p+0.01+0.6%1.785p1.785p1.61p2,127,555
1.725p-0.10-5.5%1.80p1.80p1.71p1,189,771
1.825p0.000.0%1.825p1.825p1.757p195,715
1.825p+0.025+1.4%1.829p1.829p1.756p499,497
1.80p-0.025-1.4%1.75p1.90p1.75p349,897
1.825p0.000.0%1.843p1.94p1.75p7,235
1.825p0.000.0%1.825p1.843p1.825p559
1.825p-0.075-3.9%1.843p1.94p1.75p85,472
1.90p+0.075+4.1%1.873p1.90p1.762p432,333
1.825p-0.075-3.9%1.761p1.94p1.75p297,967
1.90p+0.075+4.1%1.756p1.90p1.75p582,601
1.825p+0.075+4.3%1.775p1.852p1.70p2,644,212
1.75p0.000.0%1.75p1.835p1.70p82,308
1.75p0.000.0%1.75p1.80p1.713p32,114
1.75p0.000.0%1.75p1.835p1.712p699,817
1.75p0.000.0%1.75p1.835p1.712p148,540
1.75p-0.05-2.8%1.80p1.85p1.72p3,061,801
1.80p0.000.0%1.80p1.90p1.727p591,879
1.80p0.000.0%1.80p1.90p1.70p925,096
1.80p0.000.0%1.80p1.93p1.70p801,698
1.80p+0.025+1.4%1.775p1.90p1.70p876,765
1.775p-0.04-2.2%1.70p1.85p1.70p1,010,392
1.815p+0.055+3.1%1.75p1.815p1.651p1,948,803
1.76p+0.01+0.6%1.75p1.79p1.70p4,703,337
1.75p-0.07-3.8%1.75p1.90p1.70p5,111,674
1.82p-0.28-13.3%2.00p2.05p1.70p13,726,239
2.10p+0.10+5.0%2.00p2.10p1.881p20,332,187
2.00p0.000.0%2.00p2.10p1.90p579,253
2.00p+0.025+1.3%1.975p2.10p1.922p1,919,887
1.975p0.000.0%1.975p2.00p1.95p2,507,630
1.975p-0.015-0.8%1.975p2.04p1.88p932,792
1.99p+0.065+3.4%1.925p2.00p1.90p1,868,010
1.925p+0.05+2.7%1.875p1.99p1.831p1,814,406
1.875p-0.05-2.6%1.925p1.944p1.816p1,642,496
1.925p-0.025-1.3%1.95p1.968p1.855p2,077,451
1.95p-0.08-3.9%1.975p2.00p1.86p6,070,981
2.03p+0.08+4.1%1.975p2.05p1.90p4,972,603
1.95p-0.075-3.7%2.025p2.05p1.865p6,609,426
2.025p-0.15-6.9%2.175p2.25p2.00p2,569,676
2.175p-0.025-1.1%2.20p2.40p2.10p3,538,514
2.20p+0.02+0.9%2.25p2.38p2.10p4,116,690
2.18p-0.02-0.9%2.20p2.30p2.10p629,431
2.20p-0.05-2.2%2.25p2.335p2.10p816,879
2.25p-0.15-6.2%2.45p2.47p2.10p2,869,735
2.40p-0.06-2.4%2.85p2.94p2.40p12,036,956
2.46p+0.285+13.1%2.20p2.50p2.10p3,547,104
2.175p+0.025+1.2%2.15p2.30p2.10p2,577,553
2.15p+0.05+2.4%2.05p2.20p2.00p1,568,340
2.10p+0.05+2.4%2.05p2.10p2.00p944,166
2.05p0.000.0%2.05p2.14p2.00p552,620
2.05p-0.05-2.4%2.05p2.10p2.00p384,497
2.10p+0.10+5.0%2.00p2.10p1.90p989,850
2.00p0.000.0%2.00p2.10p1.926p178,380
2.00p+0.025+1.3%1.975p2.095p1.911p1,422,075
1.975p+0.025+1.3%1.95p2.05p1.90p344,799
1.95p+0.025+1.3%1.925p2.04p1.90p789,758
1.925p0.000.0%1.925p2.04p1.85p220,851
Ticker
LSE:GENF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
GBX

What changed lately

Latest news

All Genflow Biosciences PLC news

Genflow Biosciences PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
34 in the last 12 months · 120 in all · newest Oct 30, 2026 · oldest 2022
Decks
3 decks · latest July 2026

Where Genflow Biosciences PLC is listed

ListingExchangeCountryCurrency
LSE:GENF · Home listing · This pageLSEUnited KingdomGBX
OTC:GENFFOTCUnited StatesUSD
Frankfurt:WQ5FrankfurtGermanyEUR
Lang & Schwarz:A3DCSMLang & SchwarzGermanyEUR
LS Exchange:A3DCSMLS ExchangeGermanyEUR
Stuttgart:WQ5StuttgartGermanyEUR

Valuation

Price/book 48.5× against a median of 1.9×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
£8.58M GBP
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
48.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Genflow Biosciences PLC · LSE:GENFUS$12.06MUS$11.23Mn/an/an/a48.5×n/a0.0×n/a
Allarity Therapeutics, Inc. · NASDAQ:ALLRUS$12.56MUS$21.48Mn/a61.4×n/an/an/an/a1.40
Lobe Sciences Ltd · CSE:LOBEUS$12.52MUS$8.89Mn/an/an/a9.5×n/a0.0×0.31
Biophytis SA · EURONEXT:ALBPSUS$12.47MUS$19.44Mn/an/an/an/an/an/an/a
MIRA Pharmaceuticals, Inc. · NASDAQ:MIRAUS$12.23MUS$5.26Mn/an/an/a1.8×n/a0.0×1.48
BioCardia, Inc. · NASDAQ:BCDAUS$11.88MUS$10.22Mn/an/an/a14.2×n/a0.7×0.42
Xintela AB · OMXSTO:XINTUS$11.88MUS$11.81Mn/a39.8×n/an/an/an/an/a
Pluri Inc. · NASDAQ:PLURUS$11.85MUS$38.65Mn/a26.5×n/an/an/an/a0.53
Synlogic Inc · OTC:SYBXUS$11.76MUS$201,442n/an/an/a1.2×n/a0.0×0.50
Imugene Ltd · ASX:IMUUS$11.74MUS$14.16Mn/an/an/a2.0×n/a0.7×n/a
Radiopharm Theranostics Limited · ASX:RADUS$11.59MUS$8.85Mn/a4.8×n/a0.7×n/a0.0×n/a
Median of the othersUS$11.88MUS$11.02M33.2×1.9×0.0×0.52

Team and board

Officers

OfficerRole
Eric LeireCHIEF EXECUTIVE OFFICER
Eric LaubInvestor Relations
Guy Charles Fanneau de la HorieNON-EXECUTIVE DIRECTOR - Head of Audit Committee
Tamara JosephNon-Executive Director - Head of Governance Committee
Yassine BendiabdallahNON-EXECUTIVE DIRECTOR - Head of Remuneration Committee

Board

DirectorRole
Gad BerdugoChairperson
Guy Charles Fanneau de la HorieNON-EXECUTIVE DIRECTOR - Head of Audit Committee
Tamara JosephNon-Executive Director - Head of Governance Committee
Yassine BendiabdallahNON-EXECUTIVE DIRECTOR - Head of Remuneration Committee

Events

QuarterResultsShare move
Q2 2025Sep 30, 2025−8.1%
Q1 2025Apr 30, 2025−2.4%
Q2 2024Sep 30, 2024−4.7%
Q1 2023Apr 24, 2023+25.0%
Q2 2022Sep 30, 2022−1.9%
Q1 2022Apr 25, 2022−5.3%
Q4 2021Jan 17, 2022

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck20 slidesJuly 2026
Investor Presentation (March 2026)Investor deck20 slidesMarch 2026
Investor Presentation (March 2024)Investor deck18 slidesMarch 2024

Open Decks

Financings

RaiseDateIn US dollars
Private placement of new ordinary shares (and/or warrants)
Announced: private placement
Use of proceeds: Moving MASH program to IND-enabling stage, animal health dog trial payment and licensing, glaucoma proof of concept studies, and EU and US patent work
Feb 11, 2026
Private placement of new ordinary shares with warrants
Cancelled: £340,000 · £0.85 a share · Warrants at £1.2 for 24 months
Buyers: Eric Leire (40,000,000 new ordinary shares at 0.85 pence, to be directed to an institution for sale to a purchaser)
Insiders: Subscription by CEO and director Eric Leire, who will direct the shares to an institution for immediate sale to a purchaser
Use of proceeds: Continue the dog study while awaiting the Wallonia region grant; working capital
Oct 9, 2025US$456,978
Private placement of new ordinary shares with warrants
Closed: £440,000 raised · GBX 1.1 a share · Warrants at GBX 1.2 for 24 months
Buyers: Eric Leire (4,545,454 New Ordinary Shares); consortium of existing shareholders (35,454,546 New Ordinary Shares)
Insiders: CEO and director Eric Leire subscribed for the 40,000,000 shares, directing 35,454,546 to existing shareholders and keeping 4,545,454
Oct 9, 2025US$586,174
Private placement of new ordinary shares with warrants
Closed: £500,000 raised · GBX 0.8 a share · Warrants at GBX 1.5 for 36 months
Buyers: Eric Leire (subscription for 62,500,000 New Ordinary Shares, to be directed to an institution and sold to a purchaser)
Insiders: Subscription by CEO and director Eric Leire, who directs the shares to an institution that sells them to a purchaser at the same price
Use of proceeds: Advance a proof-of-concept trial of its therapeutic candidate in aged dogs
May 9, 2025US$665,147

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2021
Revenue00169.9K00
Cost of revenue1.09K1.20K1.03K130
Gross profit585.6K320.5K-1.03K-130
Research and development1.11M1.15M960.3K724.5K86.0K93.9K
Selling, general and administrative497.6K1.81M1.80M499.3K527.7K649.9K
Operating income-1.42M-1.59M-2.03M-1.82M-988.1K-649.9K
Depreciation and amortization1.09K1.18K1.03K129236.6K649.9K
EBITDA-1.42M-1.59M-2.03M-1.82M-751.5K0
Interest expense00038299
Income before tax-1.42M-1.59M-1.86M-1.34M-988.2K-651.0K
Income tax000099-1.09K
Net income-1.42M-1.59M-1.86M-1.34M-988.3K-651.0K
Earnings per share, basic-0.33-0.48-0.01-0.00-0.00-0.82

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2021
Cash and equivalents111.8K278.7K684.0K2.36M224.0K254.2K
Receivables339.5K105.2K384.3K258.9K52.5K19.5K
Current assets451.3K383.8K1.07M2.62M276.6K283.8K
Property, plant and equipment1.07K2.07K3.39K2.35K
Total assets452.4K385.9K1.07M2.62M276.6K283.8K
Accounts payable1.00M788.9K572.0K251.0K37.7K52.8K
Current liabilities1.00M788.9K572.0K251.0K221.4K64.8K
Total liabilities1.00M788.9K572.0K251.0K221.4K64.8K
Shareholders' equity-550.8K-403.0K499.7K2.37M55.1K219.0K
Shares outstanding426.7M334.5M292.5M292.5M292.5M796.1K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2021
Cash from operations-1.44M-1.08M-1.66M-1.37M-747.4K-439.5K
Capital spending-50-2.44K-2.48K00
Free cash flow-1.44M-1.08M-1.66M-1.37M-747.4K-439.5K
Cash from investing00-2.44K-2.48K198.5K216.5K
Cash from financing1.31M656.6K03.50M783.7K1.96M
Change in cash-127.9K-425.6K-1.66M2.13M234.8K1.74M

Open Financials

Cap table

Built by 6ix from Genflow Biosciences PLC’s releases · as of Feb 11, 2026

Common shares
594,534,781
Fully diluted
594,534,781

Fully diluted

LineShares
Common shares594,534,781

Warrants and options

Lot
Warrants · 1.20 GBX · expire about Oct 2027
Warrants · 1.50 GBX · expire about May 2028

Share count over time

CountShares
Nov 22, 2026594,534,781

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Eric LaubInvestor Relations · Since at least Sep 29, 2026
Eric LeireCHIEF EXECUTIVE OFFICER · Since at least Oct 30, 2026
Gad BerdugoChairperson · Since at least Sep 29, 2026
Guy Charles Fanneau de la HorieNON-EXECUTIVE DIRECTOR - Head of Audit Committee · Since at least Jun 29, 2026
Tamara JosephNon-Executive Director - Head of Governance Committee · Since at least Jul 13, 2026
Yassine BendiabdallahNON-EXECUTIVE DIRECTOR - Head of Remuneration Committee · Since at least Jun 29, 2026

Open People

Log in to ask 6ix AI your own questions about Genflow Biosciences PLC.